论文部分内容阅读
抗凝血酶Ⅲ(AT-Ⅲ)是一种多功能的丝氨酸蛋白酶抑制物。本文按 Anderson 方法加以改良测定AT-Ⅲ活性并观察其在临床过程中的改变及其意义。现将结果报告如下(表):急性白血病组中急粒和慢粒急变共14例均值±SD 为120.26±58.60%,完全缓解者5例为102.98±54.96%,虽高于正常组,但无显著差异。肝硬化、肝癌、急性肾功衰较正常值低,有显著差异。6例肝硬化患者临床有明显黄疸腹水及白球蛋白倒置,AT-Ⅲ均值为46.28±24.13%,有显著差异,最低值为13.26%。急性肾功衰 AT-Ⅲ范围17.98～111.47%,10例多尿期患者均值67.43±
Antithrombin III (AT-III) is a multifunctional serine protease inhibitor. This article by Anderson method to improve the determination of AT-III activity and observe its changes in the clinical course and its significance. The results are reported as follows (Table): acute leukemia group of acute and chronic catabolism of a total of 14 cases mean ± SD of 120.26 ± 58.60%, 5 cases of complete remission 102.98 ± 54.96%, although higher than the normal group, but no Significant differences. Cirrhosis, liver cancer, acute renal failure than the normal low, there are significant differences. In 6 patients with cirrhosis, jaundice ascites and white globulin were overturned. The average AT-Ⅲ was 46.28 ± 24.13%, with a significant difference of 13.26%. Acute renal failure AT-Ⅲ range 17.98 ~ 111.47%, 10 cases of polyuria patients mean 67.43 ±